A recent safety alert has been issued involving a voluntary recall of a chemotherapy medication distributed in the United States. Sun Pharma has recalled a specific batch of DOXOrubicin Hydrochloride Liposome Injection 50 mg/25 mL after the potential presence of glass particles was identified in some vials during manufacturing quality checks.
This recall is important for healthcare professionals, hospitals, pharmacists, and patients receiving chemotherapy treatments. The affected product is used in oncology care, where strict sterility and contamination control are essential due to the vulnerability of patients undergoing cancer treatment.
According to the FDA notice, the recall is being carried out at the hospital and user level in the United States.
The recalled product is:
This formulation is a liposomal version of doxorubicin, a chemotherapy agent commonly used in cancer treatment protocols. It is often prescribed for conditions such as:
Because it is administered intravenously, any contamination in the vial can create serious safety concerns.
The recall was initiated after glass particles were detected in some vials during production quality inspections.
Glass contamination in injectable medications is considered a serious pharmaceutical defect. Even microscopic particles can pose significant risks when introduced directly into the bloodstream.
The company stated that the issue was identified during internal manufacturing review and not necessarily through patient reports. At the time of the recall announcement, no adverse events had been officially reported for this specific batch.
Sun Pharma has stated that it has investigated the root cause and implemented corrective and preventive actions to avoid recurrence.
Glass particles in intravenous medications can present multiple medical risks depending on size, quantity, and patient condition.
Possible complications include:
Cancer patients are often immunocompromised, which increases their vulnerability to complications from contaminated medications.
Healthcare professionals are advised to carefully inspect injectable products and follow recall instructions strictly.
Hospitals, pharmacies, and distributors that may have received the affected lot are instructed to take immediate action.
Recommended steps include:
Sun Pharma is contacting distributors and customers directly using overnight communication channels to ensure rapid awareness.
Replacement or return arrangements are being coordinated through the company’s recall management processor.
Patients who may have received this medication do not need to take immediate action unless advised by a healthcare provider.
Key guidance includes:
Any suspected side effects should be reported through official pharmacovigilance channels.
Healthcare professionals and patients can report suspected reactions or quality issues through the FDA MedWatch program, which monitors drug safety in the United States.
Reports can be submitted online or by mail through the official FDA reporting system available at FDA MedWatch Reporting.
This system helps regulatory authorities track medication safety trends and initiate further action if needed.
The recall is being conducted with the knowledge of the U.S. Food and Drug Administration. Regulatory oversight ensures that pharmaceutical companies comply with safety standards and take corrective action when manufacturing issues are identified.
Drug recalls like this are typically classified as precautionary when potential risks exist but no confirmed widespread patient harm has been reported.
The FDA works alongside manufacturers to:
Chemotherapy drugs require extremely high manufacturing standards because they are administered to patients with weakened immune systems.
Even minor contamination can create disproportionate risks compared to standard medications. Injectable oncology drugs are especially sensitive because they bypass natural body defenses.
This recall highlights several important issues in pharmaceutical safety:
Pharmaceutical recalls involving injectable oncology drugs are relatively rare but taken very seriously due to the potential severity of outcomes.
Manufacturers typically respond by:
Sun Pharma has indicated that corrective measures have already been implemented following internal investigation.
The medication itself is widely used in cancer treatment, but this recall applies only to a specific batch suspected of contamination.
They should stop using the batch immediately and follow return instructions provided by the manufacturer.
No confirmed adverse events have been reported for this batch at the time of the recall notice.
Patients should consult their healthcare provider before making any changes to their treatment plan.
The Sun Pharma DOXOrubicin Hydrochloride Liposome Injection recall in 2026 highlights the importance of strict pharmaceutical manufacturing standards, especially for injectable chemotherapy drugs. The detection of glass particles in a production batch led to a voluntary recall to prevent potential patient harm.
Healthcare providers are advised to discontinue use of the affected lot, follow recall protocols, and report any adverse events through official FDA channels.
FDA
This article is for informational and SEO purposes only. It is not intended to provide medical advice, diagnosis, or treatment recommendations. Always consult a qualified healthcare professional before making decisions about medications or medical care.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.